Intraperitoneal hyperthermic perfusion (IPHP): Analysis of morbidity and toxicity

Research output: Contribution to journalArticlepeer-review


Intraperitoneal hyperthermic perfusion (IPHP) with a solution that contains CDDP (25 mg/m2/l) and MMC (3.3 mg/m2/l) was clinically introduced in the treatment of peritoneal carcinomatosis. Twenty-six patients underwent surgical treatment and IPHP. Peritoneal carcinomatosis was classified at laparotomy using the Japanese classification: P1 (n=3), P2 (n=5), P3 (n=15), unclassifiable (n=3). In this series of patients only the creatinine and amylase values were significant in biological toxicity evaluation. The surgical complication rate (2 duodenal fistulas) does not differ from the general extensive abdominal surgery.

Original languageEnglish
Pages (from-to)1103-1106
Number of pages4
JournalOncology Reports
Issue number6
Publication statusPublished - 1996


  • hyperthermia
  • intraperitoneal perfusion
  • peritoneal carcinomatosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Intraperitoneal hyperthermic perfusion (IPHP): Analysis of morbidity and toxicity'. Together they form a unique fingerprint.

Cite this